Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Tough-to-Treat pancreatic cancer

NCT ID NCT04896073

Summary

This study tested an oral drug called Minnelide in adults with a rare and aggressive form of pancreatic cancer that had stopped responding to prior treatments. The goal was to see if the drug could control the cancer's growth. Participants took the drug daily in repeating cycles for up to a year while doctors monitored their response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOSQUAMOUS CARCINOMA OF THE PANCREAS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

Conditions

Explore the condition pages connected to this study.